NLRP3 inflammasome inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12168012
APP PUB NO 20210308140A1
SERIAL NO

17259252

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NOVARTIS AGBASEL

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Farady, Christopher Basel, CH 6 7
Gommermann, Nina Lörrach, DE 4 7
Janser, Philipp Basel, CH 12 37
MacKay, Angela Basel, CH 5 12
Mattes, Henri Michelbach le Bas, FR 19 104
Stiefl, Nikolaus Johannes Lörrach, DE 17 102
Velcicky, Juraj Basel, CH 7 19

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 17, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 17, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 17, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00